Literature DB >> 28927341

Perceived need of, and interest in, HIV pre-exposure prophylaxis amongst men who have sex with men attending three sexual health clinics in London, UK.

Lauren Bull1, Pavle Dimitrijevic1, Sophie Beverley1, Alex Scarborough1, Sundhiya Mandalia1, Olamide Dosekun2, Tristan Barber1, Iain Reeves3, Sheena McCormack1, Michael Rayment1.   

Abstract

HIV pre-exposure prophylaxis (PrEP) has proven efficacy in reducing the risk of HIV infection in men who have sex with men (MSM), but has not yet been commissioned in the UK. The aim of this study was to investigate perceived need and benefit (or experience of) PrEP among HIV-negative MSM attending sexual health clinics. HIV-negative MSM attending three sexual health centres in London, UK were opportunistically invited to complete a questionnaire. Data collected comprised demographic data and sexual and drug use behaviours as well as questions regarding perceptions of risk and need for PrEP. Logistic regression analysis was undertaken to identify variables predicting acceptability of, and intention to use, PrEP. In addition, data were gathered in respondents already taking PrEP. Eight hundred and thirty-nine questionnaires were analysed. The median age of respondents was 35 years (IQR 28-41, range 18-78), 650 (77%) were of white ethnicity and 649 (77%) had a university education. Four hundred and fifty-six (54%) reported at least one episode of condomless anal sex in the preceding three months, 437 (52%) reported recreational drug use in the preceding three months and 311 (37%) had been diagnosed with a sexually transmitted infection within the preceding six months. Four hundred and sixty-three (64%) of 726 strongly agreed with the statement 'I think I would benefit from PrEP'. Multivariate logistic regression analysis demonstrated that having receptive anal intercourse (RAI) without condoms, having an awareness of the risk of unprotected RAI and having belief in the effectiveness of PrEP were independent predictors for someone thinking they would benefit from taking PrEP. Eight percent of respondents (59/724) had already taken or were currently taking PrEP. The results suggest that individuals at risk are likely to perceive themselves as benefiting from PrEP. The majority perceived their risk of acquiring HIV and benefit from PrEP accurately. Overall they appeared to have little concern over the use of PrEP and generally positive attitudes. Further investigation is warranted to understand why those at risk do not perceive benefit from PrEP.

Entities:  

Keywords:  High-risk behaviour; homosexual; human immunodeficiency virus; pre-exposure prophylaxis; prevention; sexual behaviour; viral disease

Mesh:

Substances:

Year:  2017        PMID: 28927341      PMCID: PMC5975944          DOI: 10.1177/0956462417730259

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  13 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

2.  FDA paves the way for pre-exposure HIV prophylaxis.

Authors:  David Holmes
Journal:  Lancet       Date:  2012-07-28       Impact factor: 79.321

3.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Authors:  Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Laurent Cotte; Isabelle Charreau; Cecile Tremblay; Jean-Marie Le Gall; Eric Cua; Armelle Pasquet; François Raffi; Claire Pintado; Christian Chidiac; Julie Chas; Pierre Charbonneau; Constance Delaugerre; Marie Suzan-Monti; Benedicte Loze; Julien Fonsart; Gilles Peytavin; Antoine Cheret; Julie Timsit; Gabriel Girard; Nicolas Lorente; Marie Préau; James F Rooney; Mark A Wainberg; David Thompson; Willy Rozenbaum; Veronique Doré; Lucie Marchand; Marie-Christine Simon; Nicolas Etien; Jean-Pierre Aboulker; Laurence Meyer; Jean-François Delfraissy
Journal:  N Engl J Med       Date:  2015-12-01       Impact factor: 91.245

4.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.

Authors:  Stephanie E Cohen; Eric Vittinghoff; Oliver Bacon; Susanne Doblecki-Lewis; Brian S Postle; Daniel J Feaster; Tim Matheson; Nikole Trainor; Robert W Blue; Yannine Estrada; Megan E Coleman; Richard Elion; Jose G Castro; Wairimu Chege; Susan S Philip; Susan Buchbinder; Michael A Kolber; Albert Y Liu
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

Review 7.  HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention.

Authors:  David P Wilson
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

8.  An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.

Authors:  David I Dolling; Monica Desai; Alan McOwan; Richard Gilson; Amanda Clarke; Martin Fisher; Gabriel Schembri; Ann K Sullivan; Nicola Mackie; Iain Reeves; Mags Portman; John Saunders; Julie Fox; Jake Bayley; Michael Brady; Christine Bowman; Charles J Lacey; Stephen Taylor; David White; Simone Antonucci; Mitzy Gafos; Sheena McCormack; Owen N Gill; David T Dunn; Anthony Nardone
Journal:  Trials       Date:  2016-03-24       Impact factor: 2.279

Review 9.  The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.

Authors:  Gabriela B Gomez; Annick Borquez; Kelsey K Case; Ana Wheelock; Anna Vassall; Catherine Hankins
Journal:  PLoS Med       Date:  2013-03-12       Impact factor: 11.069

Review 10.  How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention.

Authors:  Ingrid Young; Lisa McDaid
Journal:  AIDS Behav       Date:  2014-02
View more
  5 in total

1.  Interest in Taking HIV Pre-exposure Prophylaxis Is Associated with Behavioral Risk Indicators and Self-Perceived HIV Risk Among Men Who Have Sex with Men Attending HIV Testing Venues in Sweden.

Authors:  Tobias Herder; Anette Agardh; Per Björkman; Fredrik Månsson
Journal:  Arch Sex Behav       Date:  2020-06-03

2.  How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP.

Authors:  Victoria Pilkington; Andrew Hill; Sophie Hughes; Nneka Nwokolo; Anton Pozniak
Journal:  J Virus Erad       Date:  2018-10-01

3.  Combination prevention and HIV: a cross-sectional community survey of gay and bisexual men in London, October to December 2016.

Authors:  Louise Logan; Ibidun Fakoya; Alison Howarth; Gary Murphy; Anne M Johnson; Alison J Rodger; Fiona Burns; Anthony Nardone
Journal:  Euro Surveill       Date:  2019-06

4.  A structural equation model to predict pre-exposure prophylaxis acceptability in men who have sex with men in Leicester, UK.

Authors:  R Jaspal; B Lopes; J Bayley; P Papaloukas
Journal:  HIV Med       Date:  2018-08-30       Impact factor: 3.180

5.  Patterns of sexualised recreational drug use and its association with risk behaviours and sexual health outcomes in men who have sex with men in London, UK: a comparison of cross-sectional studies conducted in 2013 and 2016.

Authors:  Tyrone J Curtis; Alison J Rodger; Fiona Burns; Anthony Nardone; Andrew Copas; Sonali Wayal
Journal:  Sex Transm Infect       Date:  2019-11-19       Impact factor: 3.519

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.